Vir Biotechnology, Inc.
VIR
$5.53
$0.254.74%
| Weiss Ratings | VIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | VIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | VIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.40 | |||
| Price History | VIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -14.66% | |||
| 30-Day Total Return | -34.09% | |||
| 60-Day Total Return | -47.33% | |||
| 90-Day Total Return | -30.53% | |||
| Year to Date Total Return | -23.93% | |||
| 1-Year Total Return | -40.15% | |||
| 2-Year Total Return | -76.48% | |||
| 3-Year Total Return | -74.57% | |||
| 5-Year Total Return | -81.51% | |||
| 52-Week High % Change | -63.46% | |||
| 52-Week Low % Change | 6.67% | |||
| Price | VIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $14.45 | |||
| 52-Week Low Price | $4.95 | |||
| 52-Week Low Price (Date) | Apr 09, 2025 | |||
| 52-Week High Price (Date) | Jan 08, 2025 | |||
| Valuation | VIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 724.12M | |||
| Enterprise Value | -83.34M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.83 | |||
| Earnings Per Share Growth | -16.65% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 9.74 | |||
| Price/Book (Q) | 0.63 | |||
| Enterprise Value/Revenue (TTM) | -1.12 | |||
| Price | $5.53 | |||
| Enterprise Value/EBITDA (TTM) | 0.16 | |||
| Enterprise Value/EBIT | 0.16 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | VIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 136.81M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 415 906 4324 | |||
| Address | 1800 Owens Street San Francisco, CA 94158 | |||
| Website | www.vir.bio | |||
| Country | United States | |||
| Year Founded | 2016 | |||
| Profitability | VIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -719.82% | |||
| Profit Margin | -703.40% | |||
| Management Effectiveness | VIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -20.12% | |||
| Return on Equity | -- | |||
| Income Statement | VIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 74.21M | |||
| Total Revenue (TTM) | 74.21M | |||
| Revenue Per Share | $0.54 | |||
| Gross Profit (TTM) | -415.16M | |||
| EBITDA (TTM) | -519.59M | |||
| EBIT (TTM) | -534.14M | |||
| Net Income (TTM) | -521.96M | |||
| Net Income Avl. to Common (TTM) | -521.96M | |||
| Total Revenue Growth (Q YOY) | -26.29% | |||
| Earnings Growth (Q YOY) | 9.82% | |||
| EPS Diluted (TTM) | -3.83 | |||
| EPS Diluted Growth (Q YOY) | 11.72% | |||
| Balance Sheet | VIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 905.35M | |||
| Cash Per Share (Q) | $6.62 | |||
| Total Current Assets (Q) | 1.04B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.15B | |||
| Current Ratio (Q) | 8.712 | |||
| Book Value Per Share (Q) | $8.40 | |||
| Total Assets (Q) | 1.40B | |||
| Total Current Liabilities (Q) | 119.66M | |||
| Total Debt (Q) | 97.89M | |||
| Total Liabilities (Q) | 248.43M | |||
| Total Common Equity (Q) | 1.15B | |||
| Cash Flow | VIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 499.37M | |||
| Cash from Financing (TTM) | 4.39M | |||
| Net Change in Cash (TTM) | 57.40M | |||
| Levered Free Cash Flow (TTM) | -370.05M | |||
| Cash from Operations (TTM) | -446.35M | |||
